A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Company Overview We are a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary and other diseases including those that arise from aberrant signaling through the Abelson Tyrosine Kinase, and type III receptor tyrosine kinases including platelet derived growth factor receptors and proto-oncogene c-KIT ("c-KIT"). The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for Pulmonary Arterial Hypertension (PAH). IKT-001 was designed to improve the oral absorption, reduce GI side effects and enhance the safety of active pharmaceutical ingredients. IKT-001 is a prodrug of imatinib, an FDA approved treatment for certain blood and stomach cancers. We plan to seek approval from the FDA for IKT-001 in PAH as an orphan indication.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | - | - | - | - |
| Net Income | -48M | -28M | -19M | -18M | -15M | -2.8M |
| EPS | $0.47 | $-1.16 | $-3.16 | $-4.28 | $-4.86 | $-2.10 |
| Free Cash Flow | 0 | -19M | -18M | -18M | -14M | -1.1M |
| ROIC | -55.4% | - | -142.6% | -85.2% | -38.5% | -28.3% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | - | 0.01 | 0.01 | 0.00 | 0.03 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -51M | -29M | -20M | -18M | -15M | -2.8M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -65.4% | - | -173.3% | -85.8% | -38.5% | -29.1% |
| Shares Outstanding | 75M | 24M | 74M | 4M | 3M | 1M |
| Metric | 2020 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | N/A | N/A | N/A | N/A | 0 | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -2.8M | -15M | -18M | -20M | -29M | -51M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -2.8M | -15M | -18M | -19M | -28M | -48M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | -28.3% | -38.5% | -85.2% | -142.6% | N/A | -55.4% |
| ROE | -29.1% | -38.5% | -85.8% | -173.3% | N/A | -65.4% |
| ROA | -19.3% | -34.8% | -72.4% | -131.2% | -48.7% | -59.9% |
| Cash Flow | ||||||
| Op. Cash Flow | -1.1M | -14M | -17M | -18M | -19M | -26M |
| Free Cash Flow | -1.1M | -14M | -18M | -18M | -19M | 0 |
| Owner Earnings | -1.7M | -16M | -18M | -19M | -27M | -34M |
| CapEx | 0 | 0 | 243K | 14K | 0 | 0 |
| Maint. CapEx | 0 | 0 | 7K | 177K | 26K | 26K |
| Growth CapEx | N/A | N/A | 237K | 0 | N/A | 0 |
| D&A | 0 | 0 | 7K | 177K | 26K | 26K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 574K | 1.5M | 458K | 500K | 8.1M | 8.1M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||
| Net Debt | 276K | 0 | 146K | 150K | 111K | 0 |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Debt | 276K | 0 | 146K | 150K | 111K | 111K |
| Debt/Equity | 0.03 | 0.00 | 0.01 | 0.01 | N/A | 0.00 |
| Interest Coverage | -95.9 | -12862.5 | -18631.7 | N/A | N/A | N/A |
| Equity | 9.8M | 38M | 21M | 11M | N/A | 73M |
| Total Assets | 15M | 42M | 25M | 15M | 99M | 80M |
| Total Liabilities | 5.0M | 4.1M | 3.9M | 3.5M | N/A | 6.7M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | 15M | -30M | -48M | -67M | -94M | -94M |
| Working Capital | -4.7M | 38M | 21M | 11M | 95M | 95M |
| Current Assets | 55K | 42M | 24M | 14M | 98M | 98M |
| Current Liabilities | 4.7M | 4.1M | 3.7M | 3.4M | 3.7M | 3.7M |
| Per Share Data | ||||||
| EPS | -2.10 | -4.86 | -4.28 | -3.16 | -1.16 | 0.47 |
| Owner EPS | -1.26 | -5.20 | -4.22 | -0.25 | -1.15 | -0.45 |
| Book Value | 7.21 | 12.63 | 4.99 | 0.15 | N/A | 0.97 |
| Cash Flow/Share | -0.83 | -4.70 | -4.11 | -0.24 | -0.81 | -0.63 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 1.4M | 3.0M | 4.2M | 74.3M | 23.7M | 75.2M |
| Valuation | ||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | 3.6 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 7.8 | 0.7 | 0.6 | 8.3 | N/A | 1.8 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | -1.5% | -52.6% | -141.9% | -20.0% | -26.5% | N/A |
| Market Cap | 76M | 27M | 12M | 91M | 72M | 128M |
| Avg. Price | 58.08 | 23.93 | 5.85 | 2.79 | 1.93 | 1.70 |
| Year-End Price | 56.04 | 8.94 | 2.94 | 1.22 | 3.05 | 1.70 |
Inhibikase Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Inhibikase Therapeutics, Inc. (IKT) has a 5-year average return on invested capital (ROIC) of -73.7%. This is below average and may indicate limited pricing power.
Inhibikase Therapeutics, Inc. (IKT) has a market capitalization of $128M. It is classified as a small-cap stock.
Inhibikase Therapeutics, Inc. (IKT) does not currently pay a regular dividend.
Inhibikase Therapeutics, Inc. (IKT) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Inhibikase Therapeutics, Inc. (IKT) generated $-19 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Inhibikase Therapeutics, Inc. (IKT) reported earnings per share (EPS) of $-1.16 in its most recent fiscal year.
The Ledger Terminal provides 5 years of financial data for Inhibikase Therapeutics, Inc. (IKT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.